Claims

1. An oral liquid pharmaceutical composition of enzalutamide, comprising:

(i) about 2.5% to about 6% w/w of enzalutamide;

(ii) optionally, about 0.5% to about 25% w/w of an oil selected from one or more of a vegetable oil, a flavored oil, and an essential oil;

(iii) about 5% to about 85% w/w of one or both of a surfactant and a solubilizer, wherein the surfactant comprises one or more selected from tocopherol polyethylene glycol succinate surfactants, polyoxyethylene castor oil surfactants, polyoxyl hydrogenated castor oil surfactants, polyoxyl hydroxy stearate surfactants, lauroyl polyoxylglyceride and lauroyl macrogoglyceride surfactants, stearoyl polyoxylglyceride and stearoyl macrogoglyceride surfactants, and polyoxyl stearate surfactants, and the solubilizer comprises one or more selected from polyethylene glycol caprylic/capric glyceride solubilizers, a polyglyceryl oleate solubilizers, and polyoxyethylene sorbitan monooleate solubilizers;

(iv) about 5% to about 25% w/w of a co-surfactant selected from one or more of propylene glycol monolaurate Type II surfactants, oleoyl polyoxyl-6-glyceride surfactants, linoleoyl macrogolglyceride and linoleoyl polyoxylglyceride surfactants, lauroyl macrogolglyceride and lauroyl polyoxylglyceride surfactants, glycerol monocaprylocaprate Type I surfactants, and propylene glycol monocaprylate Type II surfactants;

(v) about 0.01% to about 1% w/w of an antioxidant comprising one or more selected from DL-methionine, butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), arginine, cysteine, ascorbic palmitate, sodium metabisulfite, sodium thiosulfate, propyl gallate, gamma linolenic acid, ethylenediaminetetraacetic acid (EDTA), ascorbic acid, and alpha-tocopherol;

(vi) optionally, about 0.5% to about 5% w/w of precipitation inhibitor selected one or more of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solubilizers, polyoxyethylene polyoxypropylene glycol solubilizers, polyvinylpyrrolidone solubilizers, vinylpyrrolidone-vinyl acetate copolymer solubilizers, polyvinyl alcohol/polyethylene glycol graft copolymer solubilizers,

hydroxypropyl methylcellulose solubilizers, and hypromellose acetate succinate solubilizers; and

(vii) optionally, about 1% to about 5% w/w water.

2. An oral liquid pharmaceutical composition of enzalutamide, comprising:

(i) about 2.5% to about 6% w/w of enzalutamide;

(ii) optionally, about 0.5% to about 25% w/w of an oil selected from one or more of a vegetable oil, a flavored oil, and an essential oil;

(iii) about 5% to about 65% w/w of a surfactant, wherein the surfactant comprises one or more selected from tocopherol polyethylene glycol succinate surfactants, polyoxyethylene castor oil surfactants, polyoxyl hydrogenated castor oil surfactants, polyoxyl hydroxy stearate surfactants, lauroyl polyoxylglyceride and lauroyl macrogoglyceride surfactants, stearoyl polyoxylglyceride and stearoyl macrogoglyceride surfactants, and polyoxyl stearate surfactants;

(iv) about 5% to about 30% w/w of a co-surfactant selected from one or more of propylene glycol monolaurate Type II surfactants, oleoyl polyoxyl-6-glyceride surfactants, linoleoyl macrogolglyceride and linoleoyl polyoxylglyceride surfactants, lauroyl macrogolglyceride and lauroyl polyoxylglyceride surfactants, glycerol monocaprylocaprate Type I surfactants, and propylene glycol monocaprylate Type II surfactants;

(v) about 0.01% to about 1% w/w of an antioxidant comprising one or more selected from DL-methionine, butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), arginine, cysteine, ascorbic palmitate, sodium metabisulfite, sodium thiosulfate, propyl gallate, gamma linolenic acid, ethylenediaminetetraacetic acid (EDTA), ascorbic acid, and alpha-tocopherol;

(vi) optionally, about 0.5% to about 5% w/w of precipitation inhibitor selected one or more of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solubilizers, polyoxyethylene polyoxypropylene glycol solubilizers, polyvinylpyrrolidone solubilizers, vinylpyrrolidone-vinyl acetate copolymer solubilizers, polyvinyl alcohol/polyethylene glycol graft copolymer solubilizers, hydroxypropyl methylcellulose solubilizers, and hypromellose acetate succinate solubilizers; and

(vii) optionally, about 1% to about 5% w/w water.

3. The composition of claim 1 or claim 2, comprising about 20 to about 45 mg of enzalutamide per 1 mL of the composition or about 160 mg of enzalutamide per 3.5 to 6.0 mL of the composition.

4. The composition of any one of the preceding claims, comprising: (a) about 0.5% to about 20% w/w of the oil, optionally comprising about 0.5% to about 5% w/w of the flavored oil or essential oil and about 3% to about 15% w/w of the vegetable oil, (b) about 5% to about 50% w/w of the surfactant, (c) about 5% to about 20% w/w of the co-surfactant, and (d) about 0.5% to about 1% w/w of the precipitation inhibitor.

5. The composition of any one of the preceding claims, wherein the surfactant comprises a tocopherol polyethylene glycol succinate surfactant and a polyoxyethylene castor oil surfactant, optionally wherein the tocopherol polyethylene glycol succinate surfactant is vitamin E TPGS and the polyoxyethylene castor oil surfactant is PEG 35 castor oil.

6. The composition of any one of the preceding claims, wherein the co-surfactant comprises a propylene glycol monolaurate Type II surfactant, an oleoyl polyoxyl-6-glyceride surfactant, glycerol monocaprylocaprate Type I surfactant, or a propylene glycol monocaprylate Type II surfactant, optionally wherein the propylene glycol monolaurate Type II surfactant is CAPMUL® PG-12, the oleoyl polyoxyl-6-glyceride surfactant is LABRAFIL® M 1944 CS, the glycerol monocaprylocaprate Type I surfactant is CAPMUL® MCM, and the propylene glycol monocaprylate Type II surfactant is CAPMUL® PG-8

7. The composition of any one of the preceding claims, further comprising about 10% to about 35% w/w of a co-solvent, wherein the co-solvent comprises one or more selected from diethylene glycol monoethyl ether, glycofurol, and N-methyl pyrrolidone.

8. The composition of any one of the preceding claims, comprising or further comprising about 10% to about 65% w/w of a solubilizer, wherein the solubilizer comprises one or more selected from polyethylene glycol caprylic/capric glyceride solubilizers, a polyglyceryl oleate solubilizers, and polyoxyethylene sorbitan monooleate solubilizers.

9. The composition of any one of the preceding claims, wherein the antioxidant comprises one or more selected from DL-methionine, butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), arginine, and cysteine.

10. The composition of any one of the preceding claims, further comprising one or more of a sweetening agent and a flavoring agent.

11. The composition of claim 10, wherein the sweetening agent comprises one or more selected from sucralose, ammonium glycyrrhizinate, saccharin, aspartame, acesulfame potassium, cyclamate, erythritol, and neotame and the flavoring agent comprises one or more selected from vanilla flavor, banana flavor, grapefruit flavor, strawberry flavor, raspberry flavor, bubble gum flavor, and caramel flavor.

12. The composition of any one of the preceding claims, wherein:

the oil is present and comprises peppermint oil as a flavored oil and corn oil as a vegetable oil;

the surfactant is a tocopherol polyethylene glycol succinate surfactant or a combination of a tocopherol polyethylene glycol succinate surfactant and a polyoxyethylene castor oil surfactant, optionally, wherein the surfactant is vitamin E TPGS or wherein the surfactant is vitamin E TPGS and PEG 35 castor oil;

the co-surfactant is a propylene glycol monolaurate Type II co-surfactant, an oleoyl polyoxyl-6-glyceride co-surfactant, a glycerol monocaprylocaprate Type I co-surfactant, or a propylene glycol monocaprylate Type II co-surfactant; and

the precipitation inhibitor is present and is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor.

13. The composition of any one of claims 1-3, comprising:

(i) about 2.5% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 10% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(v) about 15% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 60% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent;

(x) optionally, the flavoring agent; and

(xi) water is present in an amount of about 1.5% w/w.

14. The composition of claim 13, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises one or more selected from DL methionine, butylated hydroxy anisole (BHA), and butylated hydroxy toluene;

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla and banana.

15. The composition of any one of claims 1-3, comprising:

(i) about 2.5% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 10% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(v) about 15% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 60% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent;

(x) optionally, the flavoring agent; and

(xi) water is present in an amount of about 3% w/w.

16. The composition of claim 15, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises DL methionine;

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla and banana.

17. The composition of any one of claims 1-3, comprising:

(i) about 2.5% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 10% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(v) about 15% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 60% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent;

(x) optionally, the flavoring agent; and

(xi) water is present in an amount of about 1.5% w/w.

18. The composition of claim 17, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises DL methionine;

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla and banana.

19. The composition of any one of claims 1-3, comprising:

(i) about 2.5% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 10% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(v) about 15% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 60% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) the antioxidant;

(viii) optionally, the sweetening agent;

(ix) optionally, the flavoring agent; and

(x) water is present in an amount of about 3% w/w.

20. The composition of claim 19, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the antioxidant comprises DL methionine;

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent in present and comprises vanilla and banana.

21. The composition of any one of claims 1-3, comprising:

(i) about 2.5% w/w of enzalutamide;

(ii) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(iii) about 15% w/w of the tocopherol polyethylene glycol succinate surfactant;

(iv) about 60% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(v) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(vi) the antioxidant;

(vii) optionally, the sweetening agent;

(viii) optionally, the flavoring agent; and

(ix) water is present in an amount of about 3% w/w.

22. The composition of claim 21, wherein:

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises DL methionine;

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla and banana.

23. The composition of any one of claims 1-3, comprising:

(i) about 2.5% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 10% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(v) about 15% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 60% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent;

(x) optionally, the flavoring agent; and

(xi) water is present in an amount of about 3% w/w.

24. The composition of claim 23, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises arginine;

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla and banana.

25. The composition of claim 23, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises cysteine;

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla and banana.

26. The composition of any one of claims 1-3, comprising:

(i) about 3% w/w of enzalutamide;

(ii) about 1.0% w/w of a flavored oil;

(iii) about 3.5% w/w of a vegetable oil;

(iv) about 13% w/w of the oleoyl polyoxyl-6-glyceride co-surfactant;

(v) about 12% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 20% w/w of the diethylene glycol monoethyl ether co-solvent;

(vii) about 26% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(viii) about 0.75% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(ix) about 21% w/w of the polyoxyethylene castor oil surfactant,

(x) the antioxidant;

(xi) optionally, the sweetening agent; and

(xii) optionally, the flavoring agent.

27. The composition of claim 26, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the oleoyl polyoxyl-6-glyceride co-surfactant is LABRAFIL® M 1944 CS;

the tocopherol polyethylene glycol succinate surfactant is vitamin E TPGS;

the diethylene glycol monoethyl ether co-solvent is TRANSCUTOL® HP;

the polyethylene glycol caprylic/capric glyceride solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the polyoxyethylene castor oil surfactant is KOLLIPHOR® ELP;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

28. The composition of any one of claims 1-3, comprising:

(i) about 4% w/w of enzalutamide;

(ii) about 1.5% w/w of a flavored oil;

(iii) about 5% w/w of a vegetable oil;

(iv) about 17% w/w of the oleoyl polyoxyl-6-glyceride co-surfactant;

(v) about 6% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 25% w/w of the diethylene glycol monoethyl ether co-solvent;

(vii) about 40% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(viii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(ix) the antioxidant;

(x) optionally, the sweetening agent; and

(xi) optionally, the flavoring agent.

29. The composition of claim 28, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the oleoyl polyoxyl-6-glyceride co-surfactant is LABRAFIL® M 1944 CS;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the diethylene glycol monoethyl ether co-solvent is TRANSCUTOL® HP;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

30. The composition of any one of claims 1-3, comprising:

(i) about 3% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 12% w/w of a vegetable oil;

(iv) about 13% w/w of the oleoyl polyoxyl-6-glyceride co-surfactant;

(v) about 18% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 20% w/w of the diethylene glycol monoethyl ether co-solvent;

(vii) about 0.75% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) about 30% w/w of the polyoxyethylene castor oil surfactant,

(ix) the antioxidant;

(x) optionally, the sweetening agent; and

(xi) optionally, the flavoring agent.

31. The composition of claim 30, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the oleoyl polyoxyl-6-glyceride co-surfactant is LABRAFIL® M 1944 CS;

the tocopherol polyethylene glycol succinate surfactant is vitamin E TPGS;

the diethylene glycol monoethyl ether co-solvent is TRANSCUTOL® HP;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the polyoxyethylene castor oil surfactant is KOLLIPHOR® ELP;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

32. The composition of any one of claims 1-3, comprising:

(i) about 3% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 11% w/w of a vegetable oil;

(iv) about 7% w/w of the glycerol monocaprylocaprate Type I co-surfactant;

(v) about 17% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 55% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent; and

(x) optionally, the flavoring agent.

33. The composition of claim 32, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the glycerol monocaprylocaprate Type I co-surfactant is CAPMUL® MCM;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

34. The composition of any one of claims 1-3, comprising:

(i) about 3% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 11% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monocaprylate Type II co-surfactant;

(v) about 17% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 55% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent; and

(x) optionally, the flavoring agent.

35. The composition of claim 34, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monocaprylate Type II co-surfactant is CAPMUL® PG-8;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

36. The composition of any one of claims 1-3, comprising:

(i) about 3% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 11% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(v) about 17% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 55% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent; and

(x) optionally, the flavoring agent.

37. The composition of claim 36, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

38. The composition of any one of claims 1-3, comprising:

(i) about 3% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 12% w/w of a vegetable oil;

(iv) about 15% w/w of the oleoyl polyoxyl-6-glyceride co-surfactant;

(v) about 17% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 19% w/w of the diethylene glycol monoethyl ether co-solvent;

(vii) about 0.75% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) about 28% w/w of the polyoxyethylene castor oil surfactant,

(ix) the antioxidant;

(x) optionally, the sweetening agent; and

(xi) optionally, the flavoring agent.

39. The composition of claim 38, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the oleoyl polyoxyl-6-glyceride co-surfactant is LABRAFIL® M 1944 CS;

the tocopherol polyethylene glycol succinate surfactant is vitamin E TPGS;

the diethylene glycol monoethyl ether co-solvent is TRANSCUTOL® HP;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the polyoxyethylene castor oil surfactant is KOLLIPHOR® ELP;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

40. The composition of any one of claims 1-3, comprising:

(i) about 3% w/w of enzalutamide;

(ii) about 5% w/w of a flavored oil;

(iii) about 10% w/w of a vegetable oil;

(iv) about 7% w/w of the propylene glycol monolaurate Type II co-surfactant;

(v) about 15% w/w of the tocopherol polyethylene glycol succinate surfactant;

(vi) about 60% w/w of the polyethylene glycol caprylic/capric glyceride solubilizer;

(vii) about 0.5% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor;

(viii) the antioxidant;

(ix) optionally, the sweetening agent; and

(x) optionally, the flavoring agent.

41. The composition of claim 40, wherein:

the flavored oil is peppermint oil;

the vegetable oil is corn oil;

the propylene glycol monolaurate Type II co-surfactant is CAPMUL® PG-12;

the tocopherol polyethylene glycol succinate surfactant is D-α-tocopherol polyethylene glycol 1000 succinate surfactant;

the polyethylene glycol caprylic/capric glycerides solubilizer is ACCONON® MC8-2;

the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer precipitation inhibitor is SOLUPLUS®;

the antioxidant comprises one or more selected from butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT);

the sweetening agent is present and comprises one or more selected from sucralose and ammonium glycyrrhizinate; and

the flavoring agent is present and comprises vanilla.

42. An oral liquid pharmaceutical composition of enzalutamide, comprising:

(i) about 160 mg enzalutamide in a volume of about 2.5 to 6.0 mL;

(ii) about 0.5% to about 25% w/w of an oil selected from one or more of a vegetable oil, a flavored oil, and an essential oil;

(iii) about 5% to about 55% w/w of a surfactant, wherein the surfactant comprises one or more selected from tocopherol polyethylene glycol succinate surfactants, polyoxyethylene castor oil surfactants, polyoxyl hydrogenated castor oil surfactants, polyoxyl hydroxy stearate surfactants, lauroyl polyoxylglyceride and lauroyl macrogoglyceride surfactants, stearoyl polyoxylglyceride and stearoyl macrogoglyceride surfactants, and polyoxyl stearate surfactants;

(iv) about 5% to about 25% w/w of a co-surfactant selected from one or more of oleoyl polyoxyl-6-glyceride surfactants, linoleoyl macrogolglyceride and linoleoyl polyoxylglyceride surfactants, lauroyl macrogolglyceride and lauroyl

polyoxylglyceride surfactants, glycerol monocaprylocaprate Type I surfactants, propylene glycol monocaprylate Type II surfactants, and propylene glycol monolaurate Type II surfactants; and

(v) about 0.5% to about 5% w/w of precipitation inhibitor selected one or more of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solubilizers, polyoxyethylene polyoxypropylene glycol solubilizers, polyvinylpyrrolidone solubilizers, vinylpyrrolidone-vinyl acetate copolymer solubilizers, polyvinyl alcohol/polyethylene glycol graft copolymer solubilizers, hydroxypropyl methylcellulose solubilizers, and hypromellose acetate succinate solubilizers.

43. An oral liquid pharmaceutical composition of enzalutamide, comprising:

(i) about 3% to about 6% w/w of enzalutamide;

(ii) about 0.5% to about 25% w/w of an oil selected from one or more of a vegetable oil, a flavored oil, and an essential oil;

(iii) about 5% to about 55% w/w of a surfactant, wherein the surfactant comprises one or more selected from tocopherol polyethylene glycol succinate surfactants, polyoxyethylene castor oil surfactants, polyoxyl hydrogenated castor oil surfactants, polyoxyl hydroxy stearate surfactants, lauroyl polyoxylglyceride and lauroyl macrogoglyceride surfactants, stearoyl polyoxylglyceride and stearoyl macrogoglyceride surfactants, and polyoxyl stearate surfactants;

(iv) about 5% to about 25% w/w of a co-surfactant selected from one or more of oleoyl polyoxyl-6-glyceride surfactants, linoleoyl macrogolglyceride and linoleoyl polyoxylglyceride surfactants, lauroyl macrogolglyceride and lauroyl polyoxylglyceride surfactants, glycerol monocaprylocaprate Type I surfactants, propylene glycol monocaprylate Type II surfactants, and propylene glycol monolaurate Type II surfactants; and

(v) about 0.5% to about 5% w/w of precipitation inhibitor selected one or more of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solubilizers, polyoxyethylene polyoxypropylene glycol solubilizers, polyvinylpyrrolidone solubilizers, vinylpyrrolidone-vinyl acetate copolymer solubilizers, polyvinyl alcohol/polyethylene glycol graft copolymer solubilizers,

hydroxypropyl methylcellulose solubilizers, and hypromellose acetate succinate solubilizers.

44. The composition of any one of the preceding claims, packaged as a unit dose containing 160 mg enzalutamide.

45. The composition of any one of the preceding claims, wherein

the composition does not include caprylocaproyl polyoxyl-8 glyceride solubilizers/surfactants, optionally wherein the excluded caprylocaproyl polyoxyl-8 glyceride solubilizer/surfactant is LABRASOL® and/or LABRASOL® ALF, optionally wherein the composition does not include LABRASOL® and does not include LABRASOL® ALF;

the composition does not include polyethylene glycol, optionally wherein the excluded polyethylene glycol is polyethylene glycol 300 (PEG 300) and/or polyethylene glycol 400 (PEG 400), optionally wherein the composition does not include PEG 300 and does not include PEG 400;

the composition does not include propylene glycol; or

the composition does not include ethanol.

46. An oral liquid pharmaceutical composition according to any one of claims 1-45, for use in treating prostate cancer.

47. Use of enzalutamide in the preparation of a medicament for treating prostate cancer, wherein the medicament comprises an oral liquid pharmaceutical composition according to any one of claims 1-45.